---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-034000"
form_type: "8-K"
ticker: null
cik: "0001792581"
company_name: "Kiromic Biopharma, Inc."
filed_at: "2023-03-17T23:59:59+00:00"
generated_at: "2026-06-17T23:39:56.254350+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kiromic BioPharma receives Nasdaq delisting notice for bid price non-compliance; intends to request hearing

## Summary
- Nasdaq notified Kiromic on March 14, 2023 that it failed to regain minimum $1.00 bid price by March 13 grace period.
- Common stock (KRBP) scheduled for delisting on March 23, 2023 unless hearing is requested.
- Company intends to request hearing to stay delisting and present compliance plan.
- Hearing panel may also consider separate $2.5M stockholders' equity deficiency as additional basis for delisting.
- Panel can grant extension up to September 11, 2023; no assurance of continued listing.

## SEC filing metadata
- accession: 0001104659-23-034000
- form_type: 8-K
- cik: 0001792581
- company_name: Kiromic Biopharma, Inc.
- filed_at: 2023-03-17T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1792581/000110465923034000/0001104659-23-034000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1792581/000110465923034000/tm239172d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-034000
- JSON: https://secwatch.observer/filing/0001104659-23-034000.json
- Plain text: https://secwatch.observer/filing/0001104659-23-034000.txt

## Key facts
- Listing & Compliance Notices
  Kiromic Biopharma, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: March 14, 2023, Kiromic Biopharma, Inc. (the “Company”) received written notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that the Company did not maintain a minimum bid price of at least $1.00 for a minimum of ten (10) consecutive business days before the end of the Nasdaq grace period and, therefore, did not regain compliance with Listing Rule 5550(a)(2) by March 13, 2023, as required. As a result of the foregoing, the Staff informed the Company that its common stock would be subject to delisting from The Nasdaq Capital Market on March 23, 2023, unless the Compan
  evidence_url: https://www.sec.gov/Archives/edgar/data/1792581/000110465923034000/0001104659-23-034000-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.